Research and Markets: Asacol HD (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - 2 hrs 24 mins ago
Research and Markets (http://www.researchandmarkets.com/research/6hf8lb/asacol_hd) has announced the addition of the "Asacol HD (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
The ASCO Abstracts Are Coming
Brian Orelli, The Motley Fool - Motley Fool - Tue May 13, 5:45PM CDT
The American Society for Clinical Oncology annual meeting doesn't start until the end of this month, but investors will get a little sneak peek of what to expect when abstracts for the meeting are released at 5 p.m. Eastern on Wednesday. In the...
Final Glance: Pharmaceuticals companies
AP - Tue May 13, 5:18PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Tue May 13, 5:18PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
R.I.P. the Momentum Trade, 2012-2014
at The Street - Tue May 13, 1:39PM CDT
The momentum trade is dead. And a new momentum trade has risen to take its place.
Midday Glance: Pharmaceuticals companies
AP - Tue May 13, 12:43PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Tue May 13, 12:43PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Here's Why the Dow Knows U.S. Retail Sales Aren't as Weak as They Seem
Alex Planes, The Motley Fool - Motley Fool - Tue May 13, 12:12PM CDT
The United States' major economic data points continue to wobble between strength and weakness as we pass through springtime, never quite picking up enough steam to break away from their years-long ride down the road of mediocrity. The latest major...
Johnson & Johnson (JNJ) Crosses Pivot Point Resistance at $101.03
Comtex SmarTrend(R) - Tue May 13, 11:44AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) opened today above their pivot of $100.73 and have already reached the first level of resistance at $101.03. Investors may be interested in a cross of the next upside pivot targets of $101.55 and $102.37.
Research and Markets: Entyvio (Ulcerative Colitis) - Forecast and Market Analysis to 2022
Business Wire - Tue May 13, 10:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/79x69c/entyvio) has announced the addition of the "Entyvio (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering.
Global mHealth Monitoring And Diagnostic Medical Devices Market 2013-2019: Focus On Medical Devices With In-Built Plug-Ins For Connectivity
M2 - Tue May 13, 10:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7zxll5/mhealth) has announced the addition of the "mHealth Monitoring And Diagnostic Medical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" report to their offering. The mHealth monitoring and diagnostic devices market has been segmented into seven major product types, namely, glucose monitors, blood pressure monitors, pulse oximeters, cardiac monitors, sleep apnea monitors, multi-parameter monitoring devices and others (fetal monitors, neurological monitors) devices. The market for these devices has been extensively analyzed on the basis of factors such as healthcare and monitoring applications, geographic presence and technological developments. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2013 to 2019, considering 2012 as the base year. The mHealth monitoring and diagnostic devices market report also provides the compounded annual growth rate (CAGR) for each segment of the market for the forecast period 2013 to 2019. Geographically, the mHealth monitoring and diagnostic devices market has been segmented into four regions, namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the mHealth monitoring and diagnostic devices market report comprises a qualitative analysis of the overall market considering the factors determining market dynamics such as drivers, restraints and opportunities, along with Porter's five force analysis and market attractiveness analysis. A PESTLE analysis has also been done while estimating individual geographies in order to provide current as well as future status. The mHealth monitoring and diagnostic devices market report also provides a highlight of the competitive landscape of the market, wherein the heat map analysis of the leading players in the market in terms of products offered by the companies has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and accentuate market shares. The report concludes with the profiles of major players in the mHealth monitoring and diagnostic devices market such as AT&T, Inc., Bayer HealthCare AG, BioTelemetry, Inc. (CardioNet, Inc.), Boston Scientific Corporation, DexCom, Inc., Dr?ger AG, F. Hoffmann La-Roche Ltd., Johnson & Johnson, LifeWatch AG, Masimo Corporation, Medtronic, Inc. and Omron Healthcare. The global mHealth monitoring and diagnostic medical devices market is segmented as follows: mHealth Monitoring and Diagnostic Medical Devices Market, by Product Type - Glucose Monitors - Blood Pressure Monitors - Cardiac Monitors - Pulse Oximeters - Sleep Apnea Monitors - Multi-parameter Monitors - Others Companies Mentioned - Bayer HealthCare AG - BioTelemetry, Inc. (CardioNet, Inc.) - Boston Scientific Corporation - DexCom, Inc. - Dr?ger AG - F. Hoffmann-La Roche Ltd. - FitBit, Inc. - Fora Care Inc. - iHealth Labs, Inc. - Johnson & Johnson - LifeWatch AG - Masimo Corporation - Medisana AG - Medtronic, Inc. - Nonin Medical, Inc. - Omron Healthcare, Inc. - Withings, Inc. For more information visit http://www.researchandmarkets.com/research/7zxll5/mhealth
Early Glance: Pharmaceuticals companies
AP - Tue May 13, 9:41AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are up at 10 a.m.:
Early Glance: Medical Devices companies
AP - Tue May 13, 9:41AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Entyvio (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - Tue May 13, 8:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2s7gnj/entyvio) has announced the addition of the "Entyvio (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Takeda Pharmaceuticals developed Entyvio for the treatment of moderate to severe CD and UC. Takeda's subsidiary, Millennium Pharmaceuticals, sponsored the Entyvio clinical trials, GEMINI I, GEMINI II, and GEMINI III, as well as the ongoing GEMINI LTS trial. Entyvio has been studied in 2,700 patients in nearly 40 countries, making it the largest Phase III clinical trial program ever conducted evaluating both CD and UC patients. Scope - Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Entyvio including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Entyvio for the top eight countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK Japan and Canada. Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Entyvio (vedolizumab) 9 Appendix For more information visit http://www.researchandmarkets.com/research/2s7gnj/entyvio
Asacol HD (Ulcerative Colitis) - Forecast and Market Analysis to 2022
M2 - Tue May 13, 8:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m5sgxg/asacol_hd) has announced the addition of the "Asacol HD (Ulcerative Colitis) - Forecast and Market Analysis to 2022" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Asacol made a significant impact in the UC market, mostly thanks to mesalamine's well-known safety profile. In turn, Asacol is considered the gold standard for mesalamine products in all forms (tablets, suppositories, enemas). The active ingredient in Asacol, mesalamine, exerts its function through its anti-inflammatory and immunosuppressive actions as a COX inhibitor, a blocker of T-cell-activating cytokines, an adenosine inducer, and an antibody synthesis inhibitor. Scope - Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Asacol including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Asacol for the top ten countries from 2012 to 2022 Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of Asacol performance - Obtain sales forecast for Asacol from 2012-2022 in the top ten countries Key Topics Covered: 1 Table of Contents 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Asacol HD (mesalamine) 7 Appendix For more information visit http://www.researchandmarkets.com/research/m5sgxg/asacol_hd
Research and Markets: Global Tampons Market 2014-2018: Energizer Holdings Inc, Johnson & Johnson Inc, Kimberly-Clark Corp & Procter & Gamble Co. Dominates
Business Wire - Tue May 13, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3hjxhz/global_tampons) has announced the addition of the "Global Tampons Market 2014-2018" report to their offering.
Clinical Trial Results, Acquisitions, Healthcare Partnership, and Pricing of Senior Notes - Analyst Notes on Merck, JNJ, Chelsea, Unitedhealth and Celgene
PR Newswire - Tue May 13, 6:20AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Unitedhealth Group, Inc. (NYSE: UNH) and Celgene Corporation (NASDAQ: CELG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2377-100free.
Global Tampons Market 2014-2018: Energizer Holdings Inc, Johnson & Johnson Inc, Kimberly-Clark Corp & Procter & Gamble Co. Dominates
M2 - Tue May 13, 5:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mgbx8k/global_tampons) has announced the addition of the "Global Tampons Market 2014-2018" report to their offering. One of the key factors contributing to this market growth is the increased awareness. The Global Tampons market has also been witnessing the increasing demand from emerging economies. However, the increasing vendor competition could pose a challenge to the growth of this market. The report, the Global Tampons Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Tampons market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors dominating this space are: - Energizer Holdings Inc - Johnson & Johnson Inc - Kimberly-Clark Corp - Procter & Gamble Co. Other vendors mentioned in the report are: - First Quality Enterprises Inc - HARTMANN GROUP - Kao Corp - Lil-lets Group Ltd. - Millie & More Pty. Ltd. - Natracare LLC - Rostam Ltd. - Svenska Cellulosa Aktiebolaget - Uni-Charm Corp. Key questions answered in this report: - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/mg...al_tampons
Sabine Dandiguian Honoured as HBA Luminary by the Healthcare Businesswomen's Association (HBA)
PR Newswire - Tue May 13, 3:00AM CDT
Sabine Dandiguian, Company Group Chairman, Johnson & Johnson, Global Surgery Europe Middle East and Africa (EMEA), was honoured with an "HBA Luminary Award" assigned by the Healthcare Businesswomen's Association (HBA) at its 25th anniversary Woman of the Year event. The ceremony took place on May 1, 2014 in New York City. Sabine Dandiguian is the first and only European business leader to receive this recognition.
Research and Markets: Global Wipes Market 2014-2018: Johnson & Johnson Inc., Kao Corp., Kimberly-Clark Corp., and Procter & Gamble Co. Dominate the Market
Business Wire - Mon May 12, 2:37PM CDT
Research and Markets (http://www.researchandmarkets.com/research/j8pl3g/global_wipes) has announced the addition of the "Global Wipes Market 2014-2018: Johnson & Johnson Inc., Kao Corp., Kimberly-Clark Corp., and Procter & Gamble Co. Dominate the Market" report to their offering.